ABVX Abivax SA American Depositary Shares Загрузка... : Бычьи и медвежьи мнения аналитиков
Загрузка графика...
Лучшие сигналы
Лента
13:43
02 сен
02 сен
Author explicitly shorted more MRNA at $155 with 30% of portfolio.
Author explicitly shorted more MRNA at $155 with 30% of portfolio, while expressing excitement for NKTR, KOD, VERA and noting momentum shifts in other biotechs without clear directional calls.
23:50
31 авг
31 авг
ABVX short puts better risk/reward
Position bullish in ABVX via short puts rather than long calls, seeing better risk/reward while trimming stock exposure.
Сред.
16:49
31 авг
31 авг
ABVX M&A closer, no direction
Author says ABVX will resolve with time and sees M&A as closer rather than further; no explicit price direction given.
Сред.
13:53
31 авг
31 авг
ABVX cheap even at $5B peak sales
Buy ABVX at current levels because even using a conservative $5B minimum peak sales estimate, shares look cheap on valuation.
Сред.
16:08
26 авг
26 авг
Author compares street vs retail biotech top lists and notes RVMD approval with pricing.
Author compares street vs retail biotech top lists and notes RVMD approval with pricing expectations, but frames all names as observational research rather than personal positions.
Низ.
19:01
24 авг
24 авг
ABVX bottom is in after sentiment washout
Buy ABVX for a sentiment-washout bottom, citing prior biotech examples COGT, IMGN, and NKTR that rebounded after pessimism; possible recovery toward $130 or sideways, barring major macro deterioration.
Сред.
13:41
23 авг
23 авг
ABVX largest position, bullish on M&A and Crohn's catalysts
Author maintains largest long position in ABVX, citing M&A probability as the primary near-term bull case and Crohn's disease data as the fundamental catalyst, while shifting some equity into options given a 25% divergence vs XBI since July.
Сред.
18:37
22 авг
22 авг
Author defends their track record citing NKTR and ABVX as past 10x pitches.
Author defends their track record citing NKTR and ABVX as past 10x pitches, but this is retrospective defense, not a current position or forward call.
16:22
22 авг
22 авг
The author defends their track record by citing two past 10x winners while disputing a critic's.
The author defends their track record by citing two past 10x winners while disputing a critic's fabricated example, but makes no current forward-looking trade calls.
Низ.
13:23
21 авг
21 авг
Consensus biotech longs round-trip as regrossing starts
Degrossing used these crowded biotech longs as the ATM to fund short covering; with regrossing already starting, gross rebuild should push these names back up as flows round-trip.
Сред.
09:59
20 авг
20 авг
Crowded longs will rebound after degrossing phase.
Expects crowded high-quality longs to catch a strong bid once hedge fund gross exposure rebuilds following the current degrossing phase.
Сред.
23:38
19 авг
19 авг
The author lists speculative biotech catalysts and best ideas by therapeutic area.
The author lists speculative biotech catalysts and best ideas by therapeutic area as research/watchlist content, not explicit current positions or forward calls.
23:36
19 авг
19 авг
Top biotech picks across various therapeutic areas
Author lists these biotech names as their best ideas across various therapeutic areas with the sector near all-time highs.
Сред.
22:22
18 авг
18 авг
Author confirms holding Cytokinetics since 2024 and added at $82.80.
Author confirms holding Cytokinetics since 2024 and added at $82.80, while listing other long ideas and short candidates from a prior post without explicit current positioning.
20:20
18 авг
18 авг
ABVX long: Crohn's ph2b drives 100-130% upside
Long ABVX for 100-130% upside within a year. The author, already a holder from single digits, sees Crohn's ph2b success as the key catalyst and accepts slower enrollment if it improves the readout; current fund max-allocation and buyer fatigue explain the stalled tape.
Выс.
13:21
17 авг
17 авг
Top specialists hold as core position
Author holds in their portfolio, emphasizing net additions and that top specialists hold it as a top-five position.
Сред.
13:09
17 авг
17 авг
Author shares a net conviction chart listing multiple biotech tickers without explicit position.
Author shares a net conviction chart listing multiple biotech tickers without explicit position language, so these are indexed as watch rather than directional calls.
Низ.
13:00
17 авг
17 авг
Highlights largest single-fund new positions.
Highlights largest single-fund new positions for Q2 2026, no directional view.
Сред.
12:58
17 авг
17 авг
Reports largest aggregate Q2 fund holdings
"Reports largest aggregate Q2 2026 holdings across 95 specialist funds based on 13F filings, no directional view."
Сред.
12:53
17 авг
17 авг
Reports widest ownership across specialist funds
"Reports widest Q2 2026 ownership across 95 specialist funds based on 13F filings, no directional view."
Сред.
12:52
17 авг
17 авг
Reports most closed positions across funds
"Reports most closed positions across specialist funds in Q2 2026 excluding M&A take-outs, no directional view."
Сред.
12:50
17 авг
17 авг
Reports most reduced positions across funds
"Reports most reduced positions across specialist funds in Q2 2026 excluding M&A take-outs, no directional view."
Сред.
12:49
17 авг
17 авг
Reports most added positions across funds
"Reports most added positions across specialist funds from Q1 to Q2 2026, no directional view."
Сред.
12:31
17 авг
17 авг
Notes large aggregate Q2 fund holdings
Notes the stock is among the largest aggregate Q2 holdings across 93 funds based on 13F filings.
Сред.
12:12
17 авг
17 авг
The author lists battleground tickers without stating a position or directional view.
The author lists battleground tickers without stating a position or directional view, so they are indexed as watch only.
Низ.
11:58
17 авг
17 авг
Reports widest Q2 ownership among specialist funds
Reports the widest Q2 2026 ownership across 93 specialist funds based on 13F filings.
Сред.
11:57
17 авг
17 авг
Reports most closed positions by specialist funds
Reports the most closed positions by specialist funds in Q2 2026, excluding M&A takeouts.
Сред.
11:53
17 авг
17 авг
Reports most reduced positions by specialist funds
Reports the most reduced positions by specialist funds in Q2 2026, excluding M&A takeouts.
Сред.
11:50
17 авг
17 авг
Reports most added positions by specialist funds
Reports the most added positions by specialist funds from Q1 to Q2 2026.
Сред.
22:57
16 авг
16 авг
The author expresses a confident bullish outlook on ABVX with a positive metaphor suggesting.
The author expresses a confident bullish outlook on ABVX with a positive metaphor suggesting upcoming gains.
Об аналитическом покрытии ABVX
Buzzberg отслеживает ABVX (Abivax SA American Depositary Shares) в 11 источниках. Бычьих сигналов: 171, медвежьих: 0, от 11 аналитиков. Сентимент преимущественно бычий (52%). Всего отслеживается 326 торговых идей. За последние 7 дней: бычьих: 2, наблюдение: 2. Последние спикеры: seedy19tron, A May MD.